Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomised, Double-blinded, Controlled, Dose-escalation Trial on Safety and Efficacy of Activated Recombinant FVII Analogue (NN1731) in the Treatment of Joint Bleeds in Congenital Haemophilia Patients With Inhibitors

NCT00486278 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00486278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00486278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomised, Double-blinded, Controlled, Dose-escalation Trial on Safety and Efficacy of Activated Recombinant FVII Analogue (NN1731) in the Treatment of Joint Bleeds in Congenital Haemophilia Patients With Inhibitors
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
June 30, 2010
Enrollment
51 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, haemophilia a, haemophilia b